An engineered PD-1-based and MMP-2/9-oriented fusion protein exerts potent antitumor effects against melanoma |
Wei, Mulan
(Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Three Gorges University Medical College)
Liu, Xujie (Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College) Cao, Chunyu (Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Three Gorges University Medical College) Yang, Jianlin (Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Three Gorges University Medical College) Lv, Yafeng (Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Three Gorges University Medical College) Huang, Jiaojiao (Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Three Gorges University Medical College) Wang, Yanlin (Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Three Gorges University Medical College) Qin, Ye (Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Three Gorges University Medical College) |
1 | Godefroy E, Manches O, Dreno B et al (2011) Matrix metalloproteinase-2 conditions human dendritic cells to prime inflammatory T(H)2 cells via an IL-12- and OX40L-dependent pathway. Cancer Cell 19, 333-346 DOI |
2 | Zhou J, Jin B, Jin Y, Liu Y and Pan J (2017) The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma in vitro and in vivo. Theranostics 7, 1447-1462 DOI |
3 | Ostrand-Rosenberg S, Horn LA and Haile ST (2014) The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. J Immunol 193, 3835-3841 DOI |
4 | Simon S and Labarriere N (2017) PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy? Oncoimmunology 7, e1364828 |
5 | van de Ven R, Niemeijer AN, Stam AGM et al (2017) High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodes. ERJ Open Res 3, 1-9 |
6 | Mittendorf EA, Philips AV, Meric-Bernstam F et al (2014) PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2, 361-370 DOI |
7 | Brody R, Zhang Y, Ballas M et al (2017) PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. Lung Cancer 112, 200-215 DOI |
8 | Masugi Y, Nishihara R, Yang J et al (2017) Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut 66, 1463-1473 DOI |
9 | Howitt BE, Strickland KC, Sholl LM et al (2017) Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression. Oncoimmunology 6, e1277308 DOI |
10 | Kaunitz GJ, Cottrell TR, Lilo M et al (2017) Melanoma subtypes demonstrate distinct PD-L1 expression profiles. Lab Invest 97, 1063-1071 DOI |
11 | Herbst RS, Soria JC, Kowanetz M et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563-567 DOI |
12 | Chemnitz JM, Parry RV, Nichols KE, June CH and Riley JL (2004) SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 173, 945-954 DOI |
13 | Keir ME, Butte MJ, Freeman GJ and Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26, 677-704 DOI |
14 | Wolchok JD, Kluger H, Callahan MK et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369, 122-133 DOI |
15 | Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366, 2443-2454 DOI |
16 | Cho DC, Sosman JA, Sznol M et al (2013) Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 31, 4505-4505 |
17 | Audrito V, Serra S, Stingi A et al (2017) PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p. Oncotarget 8, 15894-15911 DOI |
18 | Obeid JM, Erdag G, Smolkin ME et al (2016) PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome. Oncoimmunology 5, e1235107 DOI |
19 | Ribas A, Puzanov I, Dummer R et al (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16, 908-918 DOI |
20 | Ribas A and Tumeh PC (2014) The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade. Clin Cancer Res 20, 4982-4984 DOI |
21 | Weber JS, D'Angelo SP, Minor D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16, 375-384 DOI |
22 | Postow MA, Chesney J, Pavlick AC et al (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372, 2006-2017 DOI |
23 | Karam A and Dorigo O (2012) MMPs in ovarian cancer as therapeutic targets. Anticancer Agents Med Chem 12, 764-772 DOI |
24 | Kessenbrock K, Plaks V and Werb Z (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141, 52-67 DOI |
25 | Egeblad M and Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2, 161-174 DOI |
26 | John A and Tuszynski G (2001) The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 7, 14-23 DOI |
27 | Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ and Kosma VM (2004) Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 10, 7621-7628 DOI |
28 | Liu Z, Li L, Yang Z et al (2010) Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma. BMC Cancer 10, 270 DOI |
29 | Roy R, Yang J and Moses MA (2009) Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 27, 5287-5297 DOI |
30 | Beckman RA, Weiner LM and Davis HM (2007) Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 109, 170-179 DOI |
31 | Li L, Huang YH, Li Y, Wang FQ, Shang BY and Zhen YS (2005) Antitumor activity of anti-type IV collagenase monoclonal antibody and its lidamycin conjugate against colon carcinoma. World J Gastroenterol 11, 4478-4483 DOI |
32 | Wang FQ, Shang BY and Zhen YS (2003) [Antitumor effects of the immunoconjugate composed of lidamycin and monoclonal antibody 3G11]. Yao Xue Xue Bao 38, 515-519 |
33 | Liu XJ, Li L, Liu XJ et al (2017) Mithramycin-loaded mPEG-PLGA nanoparticles exert potent antitumor efficacy against pancreatic carcinoma. Int J Nanomedicine 12, 5255-5269 DOI |
34 | Qin Y, Liu XJ, Li L et al (2014) MMP-2/9-oriented combinations enhance antitumor efficacy of EGFR/HER2-targeting fusion proteins and gemcitabine. Oncol Rep 32, 121-130 DOI |
35 | Holliger P and Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23, 1126-1136 DOI |
36 | Zhong G, Zhang S, Li Y et al (2010) A tandem scFv-based fusion protein and its enediyne-energized analogue show intensified therapeutic efficacy against lung carcinoma xenograft in athymic mice. Cancer Lett 295, 124-133 DOI |
37 | Hidalgo M and Eckhardt SG (2001) Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 93, 178-193 DOI |
38 | Zucker S, Cao J and Chen WT (2000) Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19, 6642-6650 DOI |
39 | Vanella V, Festino L, Strudel M, Simeone E, Grimaldi AM and Ascierto PA (2017) PD-L1 inhibitors in the pipeline: Promise and progress. Oncoimmunology 7, e1365209 |
40 | Kleffel S, Posch C, Barthel SR et al (2015) Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell 162, 1242-1256 DOI |
41 | Clark CA, Gupta HB, Sareddy G et al (2016) Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer Res 76, 6964-6974 DOI |
42 | Almozyan S, Colak D, Mansour F et al (2017) PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation. Int J Cancer 141, 1402-1412 DOI |